Paloma Partners’s Accelerate Diagnostics AXDX Stock Holding History

Paloma Partners’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,498	Closed	-$130K	–	1765
2021 Q4	$130K	Buy	+2,498	New	+$139K	﹤0.01%	1716

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Paloma Partners's AXDX Position: Q1 2022 in Review

Paloma Partners sold out of Accelerate Diagnostics (AXDX) in Q1 2022, closing a stake of 2,498 shares — an estimated $130K sold.

Paloma Partners first reported a position in AXDX in Q4 2021 and held it in 1 quarter. The position peaked at $130K in Q4 2021. 106 funds tracked by Wall St. Rank hold AXDX as of Q1 2022.

Paloma Partners reported no remaining Accelerate Diagnostics position as of Q1 2022 after selling out during the quarter.
Paloma Partners sold 2,498 Accelerate Diagnostics shares in Q1 2022, an estimated $130K.
Paloma Partners first reported a position in Accelerate Diagnostics in Q4 2021 and held it in 1 quarter.
Paloma Partners's Accelerate Diagnostics position peaked at $130K in Q4 2021.
106 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.